OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Hematology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
D-dimer level in COVID-19 infection: a systematic review	229
Genetic risk factors for venous thromboembolism	48
Evidence-based indications of platelet-rich plasma therapy	46
A review of FDA-approved acute myeloid leukemia therapies beyond ‘7 + 3’	31
Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia	30
COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis	27
Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians	26
The biology and management of dyskeratosis congenita and related disorders of telomeres	23
Complement activation and coagulopathy - an ominous duo in COVID19	21
Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma	20
Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia	20
Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis	19
The spectrum of beta-thalassemia mutations in the 22 Arab countries: a systematic review	19
Avapritinib for Systemic Mastocytosis	18
Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases	18
Prophylaxis for hemophilia A without inhibitors: treatment options and considerations	18
The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas	18
Safety of FLT3 inhibitors in patients with acute myeloid leukemia	17
Immune thrombocytopenia	16
Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors	16
Managing patients with hematological malignancies during COVID-19 pandemic	15
Hemostatic defects in massive transfusion: an update and treatment recommendations	15
Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia	15
Hematological manifestations and complications of Gaucher disease	14
Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021?	14

Voxelotor for the treatment of sickle cell disease	13
Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies	13
Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment	13
Apoptosis targeted therapies in acute myeloid leukemia: an update	13
Renal disease associated with chronic myeloproliferative neoplasms	12
Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development	12
MRI detection of brain abnormality in sickle cell disease	12
Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients	12
Glucose-regulated protein 78 (GRP78) as a potential novel biomarker and therapeutic target in multiple myeloma	11
Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review	11
Evolution of the role of haploidentical stem cell transplantation: past, present, and future	11
Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma	11
Screening tools for hereditary hemolytic anemia: new concepts and strategies	11
Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?	11
Pharmacological management of rare coagulation factor deficiencies besides hemophilia	10
Biomarkers for acute and chronic graft versus host disease: state of the art	10
COVID-19 in benign hematology: emerging challenges and special considerations for healthcare professionals	10
What is the future of patient-reported outcomes in sickle-cell disease?	10
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for mucocutaneous bleeding disorders	10
Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie’s choice for patients with relapsed refractory multiple myeloma	10
Sickle cell disease as a vascular disorder	10
Overcoming the challenges of treating hemophilia in resource-limited nations: a focus on medication access and adherence	9
Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies	9
Immunodeficiency-associated Hodgkin lymphoma	9
Rectal colonization with multidrug-resistant gram-negative bacteria in patients with hematological malignancies: a prospective study	9
The advantages and risks of ruxolitinib for the treatment of polycythemia vera	8
Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia	8
Recent guidelines for high-dose chemotherapy and autologous stem cell transplant for systemic AL amyloidosis: a practitioner’s perspective	8
Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia	8
Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies	8
A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura	8
Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?	8
Post-COVID-19 hematologic complications: a systematic review	8
Cardiotoxicity of BTK inhibitors: ibrutinib and beyond	8
Targeting CD123 in BPDCN: an emerging field	8
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding	8
Acute chest syndrome of sickle cell disease: genetics, risk factors, prognosis, and management	8
Efficacy and safety of thrombopoietin receptor agonists in the treatment of thrombocytopenia after hematopoietic stem cell transplantation: a meta-analysis and systematic review	7
A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma	7
A review of current induction strategies and emerging prognostic factors in the management of children and adolescents with acute lymphoblastic leukemia	7
What COVID-19 can mean for people with hemophilia beyond the infection risk	7
Strategies to increase access to basic sickle cell disease care in low- and middle-income countries	7
Exercise and anemia in cancer patients: could it make the difference?	7
Chronic lymphocytic leukemia prognostic models in real life: still a long way off	7
Emerging pharmacotherapies for elderly acute myeloid leukemia patients	7
CD123-targeted therapy in acute myeloid leukemia	7
The National Hemophilia Foundation State of the Science Research Summit initiative: executive summary	7
Copper deficiency, a rare but correctable cause of pancytopenia: a review of literature	7
Identification and management of fetal anemia due to hemolytic disease	7
The role of platelets, neutrophils and endothelium in COVID-19 infection	7

Applying World Health Organization 2020 guidelines on physical activity and sedentary behavior to people with hemophilia	7
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia	7
A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma	7
Association of tuberculosis in patients with chronic myeloid leukemia: a treatment proposal based on literature review	7
Chronic neutropenia: how best to assess severity and approach management?	7
Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice	6
Optimizing outcomes for haploidentical hematopoietic stem cell transplantation in severe aplastic anemia with intensive GVHD prophylaxis: a review of current findings	6
Palliative care for patients with hematologic malignancies: are we meeting patients’ needs early enough?	6
Resource limited centres can deliver treatment for children with acute lymphoblastic leukaemia with risk-stratified minimal residual disease based UKALL 2003 protocol with no modification and a good o	6
Hematopoietic stem cell transplantation for classical inherited bone marrow failure syndromes: an update	6
Cardiovascular involvement in patients affected by multiple myeloma: a comprehensive review of recent advances	6
Hemophilic arthropathy: a teaching approach devoted to hemophilia treaters in under-development countries	6
Consanguineous marriage and rare bleeding disorders	6
Complications of hemophilia in the elbow: current management	6
Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review	6
Analysis of Hb levels and degree of anemia in relation to genotype in 615 patients with hemoglobin H disease	6
The value of the red cell distribution width index versus other parameters in the differentiation between iron deficiency anemia and beta thalassemia trait among children in Mosul, Iraq	6
A critical evaluation of crizanlizumab for the treatment of sickle cell disease	6
The clinical management of factor XI deficiency in pregnant women	6
Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients	6
Developments in identifying and managing mucormycosis in hematologic cancer patients	6
Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura	6
Management of patients with antiphospholipid antibodies: what to do in laboratory scenarios that do not fit the guidelines	5
Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?	5
The relationship between anemia and obesity	5
Hemostatic therapy as a management strategy for acquired hemophilia: what does the future hold?	5
Synovitis in hemophilia: preventing, detecting, and treating joint bleeds	5
Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in Madrid	5
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders	5
Outcomes and long-term effects of hematopoietic stem cell transplant in sickle cell disease	5
Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?	5
An evaluation of ferric derisomaltose as a treatment for anemia	5
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside	5
An update on the pathogenesis and diagnosis of thrombotic thrombocytopenic purpura	5
Evolution of viscoelastic coagulation testing	5
Construction of a DLBCL Prognostic Signature Based on Tumor Microenvironment	5
Thrombotic events in children and adolescent patients with SARS-CoV-2 infection: a systematic review with meta-analysis on incidence and management	5
Total knee arthroplasty in hemophilia: lessons learned and projections of what’s next for hemophilic knee joint health	5
Selinexor for the treatment of patients with previously treated multiple myeloma	5
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors	5
Bispecific antibodies in acute lymphoblastic leukemia therapy	5
How low risk are low risk myelodysplastic syndromes?	5
Immunomodulators in newly diagnosed multiple myeloma: current and future concepts	5
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia	5